Gilead Entered into an Exclusive Option and Collaboration Agreement with MacroGenics to Develop MGD024
Shots:
- MacroGenics will receive $60M up front, ~$1.7B in target nomination, option fees, development, regulatory & commercial milestones along with tiered, double-digit royalties on global net sales of MGD024 and a flat royalty under 2 research programs
- Gilead gets an option to license MGD024 for blood cancers incl. AML & MDS. MacroGenics will lead an ongoing P-I study incl. a dose escalation & expansion segment to evaluate MGD024 as monothx. & in combination with other therapies across multiple indications
- The collaboration will complement Gilead’s portfolio strengths in the immuno-oncology and hematology franchise. The therapy has the potential to reduce CRS and permit intermittent dosing through a longer half-life for AML & MDS
Ref: Businesswire | Image: Gilead
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
